2014 Communication Insurance Coverage and Processing 
Putting Patients First Blog
JANUARY 10, 2024
Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.
Putting Patients First Blog
MARCH 4, 2024
Under the new Manufacturer Discount Program, manufacturers will be required to provide discounts on applicable drugs during the initial coverage phase and catastrophic phase of the defined standard Part D drug benefit.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Putting Patients First Blog
SEPTEMBER 9, 2024
16 We encourage CMS to continue refining these data collection processes to ensure they capture meaningful and actionable information. We believe this process is crucial for adapting the payment system to evolving clinical practices and emerging medical technologies.
Putting Patients First Blog
JULY 15, 2024
The DDIWG should actively seek input from individuals with disabilities who also belong to other marginalized groups, such as people of color, LGBTQ+ individuals, and low-income communities. This process respects their autonomy by involving them in decision-making to the extent that they are able.
Putting Patients First Blog
SEPTEMBER 9, 2024
The continuation of audio-only communication options remains essential. As these technologies become increasingly integral to patient care, it is essential for CMS to develop clear and consistent guidelines for the payment and coverage of AI-enabled services. CY 2025 PFS proposed rule).
Pharmaceutical Technology
NOVEMBER 30, 2022
The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Novo Nordisk is another company leading the charge in this field.
Pharmaceutical Technology
NOVEMBER 30, 2022
The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Novo Nordisk is another company leading the charge in this field.
Expert insights. Personalized for you.
40 
Let's personalize your content